Prostate cancer localization with 18fluorine fluorocholine positron emission tomography

被引:89
作者
Kwee, SA [1 ]
Coel, MN [1 ]
Lim, J [1 ]
Ko, JHP [1 ]
机构
[1] Univ Hawaii, Queens Med Ctr, Dept Nucl Med, Hamamatsu Queens PET Imaging Ctr, Honolulu, HI 96813 USA
关键词
prostate; tomography; emission-computed; prostatic neoplasms; neoplasm staging;
D O I
10.1097/01.ju.0000142099.80156.85
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated positron emission tomography (PET) with 18 fluorine fluorocholine (F-18 FCH) for the pretreatment localization of prostate cancer. Materials and Methods: A total of 17 patients with prostate cancer who had not yet received treatment for the disease underwent whole body PET following intravenous administration of 3.3 to 4 MBq/kg F-18 FCH. PET findings were compared with the results of prostate sextant biopsy and other imaging studies, and the clinical course. Tracer uptake in prostate sextants was measured as a maximum standardized uptake value (SUVmax) and evaluated as a predictor of the prostate sextant biopsy result by ROC analysis. Results: Prostate sextants positive for malignancy on biopsy demonstrated significantly higher SLTVmax than biopsy negative sextants (mean 5.5 vs 3.3, p <0.001). In all 6 cases in which biopsy identified malignancy on only 1 side of the prostate it was possible to identify correctly the affected side based on higher SUVmax. Area under the ROC curve for SUVmax as a discriminator of biopsy positive sextants was 0.86. In 2 patients PET demonstrated areas of abnormal uptake in the retroperitoneum. Computerized tomography confirmed the presence of retroperitoneal lymphadenopathy in these areas. In the 2 patients these lesions regressed following hormonal treatment for prostate cancer. Conclusions: Malignant tumors in the prostate gland can be localized based on a standardized regional measurement of F-18 FCH uptake. PET with F-18 FCH is potentially useful for staging and localizing prostate cancer.
引用
收藏
页码:252 / 255
页数:4
相关论文
共 20 条
  • [1] Aboagye EO, 1999, CANCER RES, V59, P80
  • [2] Ackerstaff E, 2001, CANCER RES, V61, P3599
  • [3] CHARACTERIZATION OF HUMAN PROSTATE-CANCER, BENIGN PROSTATIC HYPERPLASIA AND NORMAL PROSTATE BY IN-VITRO H-1 AND P-31 MAGNETIC-RESONANCE SPECTROSCOPY
    CORNEL, EB
    SMITS, GAHJ
    OOSTERHOF, GON
    KARTHAUS, HFM
    DEBRUYNE, FMJ
    SCHALKEN, JA
    HEERSCHAP, A
    [J]. JOURNAL OF UROLOGY, 1993, 150 (06) : 2019 - 2024
  • [4] DeGrado TR, 2001, CANCER RES, V61, P110
  • [5] DeGrado TR, 2001, J NUCL MED, V42, P1805
  • [6] Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men
    Djavan, B
    Zlotta, A
    Remzi, M
    Ghawidel, K
    Basharkhah, A
    Schulman, CC
    Marberger, M
    [J]. JOURNAL OF UROLOGY, 2000, 163 (04) : 1144 - 1148
  • [7] El-Gabry EA, 2001, ONCOLOGY-NY, V15, P325
  • [8] The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer
    Epstein, JI
    Walsh, PC
    Akingba, G
    Carter, HB
    [J]. JOURNAL OF UROLOGY, 1999, 162 (05) : 1649 - 1652
  • [9] System for robotically assisted prostate biopsy and therapy with intraoperative CT guidance
    Fichtinger, G
    DeWeese, TL
    Patriciu, A
    Tanacs, A
    Mazilu, D
    Anderson, JH
    Masamune, K
    Taylor, RH
    Stoianovici, D
    [J]. ACADEMIC RADIOLOGY, 2002, 9 (01) : 60 - 74
  • [10] A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER
    GANN, PH
    HENNEKENS, CH
    STAMPFER, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (04): : 289 - 294